Literature DB >> 35983425

Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

Angeliki Meritsi1, Dimitra Latsou2, Emanuel Manesis3, Ilias Gatos4, Ioannis Theotokas4, Pavlos Zoumpoulis4, Stamatia Rapti5, Eustathios Tsitsopoulos5, Hariklia Moshoyianni6, Spilios Manolakopoulos7, Dimitrios Pektasides8, Anastasia Thanopoulou1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.
© 2022 by the American Diabetes Association.

Entities:  

Year:  2022        PMID： 35983425      PMCID： PMC9331611          DOI： 10.2337/cd21-0104

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


  41 in total

1.  Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease.

Authors:  Gabriela Ruffillo; Eduardo Fassio; Estela Alvarez; Graciela Landeira; Cristina Longo; Nora Domínguez; Gisela Gualano
Journal:  J Hepatol       Date:  2010-08-22       Impact factor: 25.083

Review 2.  NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.

Authors:  Elisabetta Bugianesi; Ester Vanni; Giulio Marchesini
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

Review 3.  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021.

Authors: 
Journal:  Diabetes Care       Date:  2021-01       Impact factor: 19.112

Review 4.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.

Authors:  Fernando Bril; Kenneth Cusi
Journal:  Diabetes Care       Date:  2017-03       Impact factor: 19.112

Review 5.  APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: Systematic review and meta-analysis.

Authors:  Magdy Amin El Serafy; Abdel Meguid Kassem; Heba Omar; Mohammad Shaaban Mahfouz; Maissa El Said El Raziky
Journal:  Arab J Gastroenterol       Date:  2017-06-01       Impact factor: 2.076

6.  Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

Authors:  Robert P Myers; Marie Hélène Tainturier; Vlad Ratziu; Annie Piton; Vincent Thibault; Françoise Imbert-Bismut; Djamila Messous; Frederic Charlotte; Vincent Di Martino; Yves Benhamou; Thierry Poynard
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

7.  Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.

Authors:  I Doycheva; J Cui; P Nguyen; E A Costa; J Hooker; H Hofflich; R Bettencourt; S Brouha; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2015-09-15       Impact factor: 8.171

8.  Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.

Authors:  A Mantovani; T Turino; M G Lando; K Gjini; C D Byrne; C Zusi; F Ravaioli; A Colecchia; C Maffeis; G Salvagno; G Lippi; E Bonora; G Targher
Journal:  Diabetes Metab       Date:  2019-11-28       Impact factor: 6.041

Review 9.  Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study.

Authors:  Wenjing Sun; Hongli Cui; Ning Li; Yanling Wei; Shujie Lai; Yang Yang; Xinru Yin; Dong-Feng Chen
Journal:  Hepatol Res       Date:  2016-02-16       Impact factor: 4.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.